When did Theravance Biopharma report Q4 2024 earnings?

Theravance Biopharma (TBPH) reported Q4 2024 earnings on February 26, 2025 after market close.

What were Theravance Biopharma's Q4 2024 revenue and EPS?

Theravance Biopharma reported revenue of $18.8M and eps of $-0.05 for Q4 2024.

Did Theravance Biopharma beat estimates in Q4 2024?

Revenue beat the consensus estimate of $17.1M by $1.7M. EPS beat the consensus estimate of $-0.05 by $0.00.

Where can I find Theravance Biopharma's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001558370-25-002447) directly on SEC EDGAR. The filing index links above go to sec.gov.

Theravance Biopharma TBPH Q4 2024 Annual earnings

Reported February 26, 2025 · After market close

Revenue$18.8MBeat by $1.7M

EPS-$0.05In line

Revenue estimate$17.1M

EPS estimate-$0.05

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$22.5M

EPS estimate$0.07

Financials

Q4 2024

Income statement

See full

Revenue$18.8M+6.8%

Operating income-$9.2M-47.4%

Net income-$15.5M-82.5%

EPS (diluted)-$0.31-82.4%

Balance sheet

See full

Cash & equivalents$37.8M-4.4%

Total debt$49.8M+1.3%

Total equity$175.5M-17.6%

Total assets$354.2M-7.3%

Cash flow

See full

Operating cash flow-$902.0K-5.6%

CapEx$190.0K-71.9%

Free cash flow-$1.1M+28.7%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$462.73M-16.7%

Enterprise value$474.75M-16.0%

P/S7.2×-2.5×

Profitability

See full

Operating margin-72.9%-14.7pp

Net margin-87.6%-7.1pp

FCF margin-18.4%-7.2pp

Returns & leverage

See full

Return on equity-29%+75.7pp

Debt / equity0.3×+0.1×

Current ratio5×-0.4×

Segments

By segment

See full

Single Reportable$18.8M+30.6%

Versus estimates

Revenue

Q1 2026$17.7MMiss by $84.3K Q4 2025$45.9MMiss by $10.7M Q3 2025$20.0MMiss by $23.1M Q2 2025$26.2MBeat by $7.5M Q1 2025$15.4MMiss by $712.0K

Q4 2024$18.8MBeat by $1.7M

Diluted EPS

Q1 2026-$0.10Miss by $0.12 Q4 2025$0.06Miss by $0.38 Q3 2025$0.04Beat by $0.07 Q2 2025-$0.08Beat by $0.06 Q1 2025-$0.17Miss by $0.06

Q4 2024-$0.05In line

Ask the moment Theravance Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Theravance Biopharma report Q4 2024 earnings?: Theravance Biopharma (TBPH) reported Q4 2024 earnings on February 26, 2025 after market close.
What were Theravance Biopharma's Q4 2024 revenue and EPS?: Theravance Biopharma reported revenue of $18.8M and eps of $-0.05 for Q4 2024.
Did Theravance Biopharma beat estimates in Q4 2024?: Revenue beat the consensus estimate of $17.1M by $1.7M. EPS beat the consensus estimate of $-0.05 by $0.00.
Where can I find Theravance Biopharma's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-002447) directly on SEC EDGAR. The filing index links above go to sec.gov.